Loading clinical trials...

COMPLETEDNA

Evaluation of a Johnson & Johnson Vision Care Investigational Contact Lens Compared to a Marketed Monthly Replacement Contact Lens

NCT02515994•Johnson & Johnson Vision Care, Inc.

Summary

Randomized, double-masked, controlled, 2-arm parallel group, multi-site, 3-month dispensing study of Johnson \& Johnson Vision Care, Inc. (JJVCI) Investigational contact lens, compared with a marketed, monthly replacement contact lens. Subjects will wear the JJVCI investigational contact lenses on a daily wear basis.

Detailed Description

Objective of the study is to demonstrate the safety and efficacy of the JJVCI investigational contact lens by comparison to the marketed, monthly replacement contact lens, both worn for thirty days on a daily wear modality.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
•The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
•The subject must be at least 18 years of age.
•The subject's vertex corrected spherical equivalent distance refraction must be in the range of -1.00 to -6.00 in each eye.
•The subject's refractive cylinder must be ≤ 1.00 Diopters in each eye.
•The subject must have best corrected visual acuity of 20/25 or better in each eye.
•Subjects should own a wearable pair of spectacles.
•The subject must be an adapted frequent replacement daily wear spherical silicone hydrogel soft contact lens wearer in both eyes.
•The subject must have normal eyes (i.e., no ocular medications or infections of any type).
•Subjects must be able and willing to wear the study lenses at least 6 hours a day, a minimum of 4 days per week

Exclusion Criteria

•Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
•Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
•Use of any of the following medications within 1 week prior to enrollment: oral retinoid isotretinoin (e.g. Accutane), oral tetracyclines, topical scopolamine, oral (e.g. Seldane, Chlor-Trimeton, and Benadryl) and ophthalmic antihistamines, oral phenothiazines (e.g., Haldol, Mellaril, Thorazine, Elavil, Pamelor, Compazine), oral and ophthalmic Beta-adrenergic blockers (e.g., Propranolol, Timolol, and Practolol), systemic steroids, and any prescribed or over the counter (OTC) ocular medication.
•Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion by keratometry.
•Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy, photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK), etc.).
•Any grade 2 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear.
•Any known hypersensitivity or allergic reaction to Optifree®Puremoist® multi-purpose care solution or Eye-Cept® rewetting drop solution
•Any ocular infection, allergy or clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca, ocular hypertension), or ocular conditions (e.g. strabismus), which might interfere with the study.
•Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
•Daily disposables, extended wear, monovision or multi-focal contact lens correction.
+3 more criteria

Locations (10)

Vue Optical Boutique

Jacksonville, Florida, United States

Omega Vision Center, PA / Sabal Eye Care

Longwood, Florida, United States

Eyecare Associates

Bloomington, Illinois, United States

Advantage Eyecare Associates, LLC

Broadway Pittsburg, Kansas, United States

Dr. Debbie H. Kim, OD

Closter, New Jersey, United States

Sacco Eye Group

Vestal, New York, United States

Pickens Family Eye Care

Pickens, South Carolina, United States

Premier Vision

Amarillo, Texas, United States

William J. Bogus OD

Salt Lake City, Utah, United States

Timothy R. Poling, OD

Salem, Virginia, United States

Key Dates

Start Date

July 1, 2015

Primary Completion Date

November 1, 2015

Completion Date

November 1, 2015

Last Updated

July 15, 2016

Enrollment

224

ACTUAL participants

Conditions

Refractive Error

Interventions

senofilcon C

DEVICE

comfilcon A

DEVICE

Cognitive Level Enhancement Through Vision Exams and Refraction

NCT05458323

Refractive Errors

View study

RECRUITING

Clinical Data Collection of Myopic Patients After PTK-PRK With CZM MEL 90 Excimer Laser

NCT06996353

Refractive Errors

View study

RECRUITINGNA

Optimizing Light Exposure for Myopia Prevention and Control (LightSPAN)

NCT06631339

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 15, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of a Johnson & Johnson Vision Care Investigational Contact Lens Compared to a Marketed Monthly Replacement Contact Lens

Inclusion Criteria

Exclusion Criteria

Cognitive Level Enhancement Through Vision Exams and Refraction

Clinical Data Collection of Myopic Patients After PTK-PRK With CZM MEL 90 Excimer Laser

Optimizing Light Exposure for Myopia Prevention and Control (LightSPAN)

Measuring Changes In Choroidal Thickness Induced By Prototype Soft Contact Lenses Worn For 1 Hour

The Objective of This Study is to Evaluate the Perfomance of a Photorefraction Device for Screening Ametropia in Children. Eligible Participants Will Undergo Multiple Refractive Error Measurements, Visual Acuity and Strabismus Assessments During a Single Evaluation Visit.

Correcting Myopia Among Secondary School Children to Increase Academic High School Attendance Rates in Rural Communities